Our team of experts also specializes in caring for leukemia in patients with Fanconi anemia, Down syndrome, and for those with post-transplant lymphoma and lymphoproliferative disorder.
Among our many treatment options is blood and marrow transplantation. The pediatric blood and marrow transplantation program at Cincinnati Children’s is one of the largest in the country and an international leader in the development of new transplant regimens for patients with leukemia, lymphoma and myelodysplasia. We have performed more than 1,300 blood and marrow transplants and developed transplant procedures that are now the standard of care in 240 cancer centers throughout North America.
Leaders in Innovative Research
Cincinnati Children’s also is a major center for pediatric cancer research. Our integrated team of physicians and researchers is at the forefront of developing more effective treatments for very high risk and relapsed disease.
Our physicians and researchers also play leading roles in national and international clinical studies of new cancer treatments through the Children’s Oncology Group, the National Cancer Institute's Pediatric Phase I Consortium and other national research institutions.
Our focus on research provides patients with early access to new anticancer therapies, sometimes years before they become widely available. We are the only site in Ohio, and one of just a few nationwide, to offer pediatric Phase I clinical trials of the newest cancer therapies.
The director of the Leukemia and Lymphoma Program is John P. Perentesis, MD, FAAP, who also serves as director of the Cancer Program at Cincinnati Children’s. Dr. Perentesis is an expert in leukemia and lymphoma and is leading national efforts to develop the next generation of therapies for these diseases.
